Bruce L. Claflin Sells 200 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Free Report) Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

IDEXX Laboratories Trading Down 2.2 %

Shares of NASDAQ IDXX opened at $518.44 on Wednesday. The stock has a fifty day simple moving average of $511.06 and a 200-day simple moving average of $522.11. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $42.82 billion, a PE ratio of 50.19, a PEG ratio of 4.28 and a beta of 1.27.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors have recently bought and sold shares of the company. Valley National Advisers Inc. boosted its stake in shares of IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the period. Riverview Trust Co acquired a new stake in IDEXX Laboratories during the 1st quarter worth approximately $26,000. Crewe Advisors LLC purchased a new position in IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Geo Capital Gestora de Recursos Ltd acquired a new position in shares of IDEXX Laboratories in the third quarter worth $28,000. Finally, Covestor Ltd increased its position in shares of IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after acquiring an additional 28 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IDXX. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. Barclays cut their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, May 14th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a research note on Tuesday, January 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $580.38.

View Our Latest Stock Report on IDXX

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Featured Stories

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.